Drug profile · INN
panobinostat lactate
FARYDAK
panobinostat lactate (FARYDAK) is a histone deacetylase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — panobinostat lactate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
panobinostat lactate (FARYDAK) is a histone deacetylase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Histone deacetylase inhibitor
Primary target: Histone deacetylase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is panobinostat lactate?
panobinostat lactate (FARYDAK) is a histone deacetylase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for panobinostat lactate?
FARYDAK is a marketed brand name for panobinostat lactate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of panobinostat lactate?
panobinostat lactate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.